BH3-only proteins couple diverse stress signals to the evolutionarily conserved mitochondrial apoptosis pathway. Previously, we reported that the activation of the BH3-only protein p53-up-regulated mediator of apoptosis (Puma) was necessary and sufficient for endoplasmic reticulum (ER) stress- and proteasome inhibition-induced apoptosis in neuroblastoma and other cancer cells. Defects in protein quality control have also been suggested to be a key event in ALS, a fatal neurodegenerative condition characterized by motoneuron degeneration. Using the SOD1(G93A) mouse model as well as human post mortem samples from ALS patients, we show evidence for increased ER stress and defects in protein degradation in motoneurons during disease progression. Before symptom onset, we detected a significant up-regulation of Puma in motoneurons of SOD1(G93A) mice. Genetic deletion of puma significantly improved motoneuron survival and delayed disease onset and motor dysfunction in SOD1(G93A) mice. However, it had no significant effect on lifespan, suggesting that other ER stress-related cell-death proteins or other factors, such as excitotoxicity, necrosis, or inflammatory injury, may contribute at later disease stages. Indeed, further experiments using cultured motoneurons revealed that genetic deletion of puma protected motoneurons against ER stress-induced apoptosis but showed no effect against excitotoxic injury. These findings demonstrate that a single BH3-only protein, the ER stress-associated protein Puma, plays an important role during the early stages of chronic neurodegeneration in vivo.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2154478PMC
http://dx.doi.org/10.1073/pnas.0707906105DOI Listing

Publication Analysis

Top Keywords

bh3-only protein
12
protein puma
8
motoneurons stress-induced
8
stress-induced apoptosis
8
defects protein
8
sod1g93a mice
8
genetic deletion
8
deletion puma
8
protein
6
puma
6

Similar Publications

Tipping the balance of cell death: alternative splicing as a source of MCL-1S in cancer.

Cell Death Dis

December 2024

Department of Molecular Biology of Cancer, Medical University of Lodz, 6/8 Mazowiecka Street, 92-215, Lodz, Poland.

Apoptosis-regulating proteins from the B-cell lymphoma-2 (BCL-2) family are of continued interest as they represent promising targets for anti-cancer therapies. Myeloid cell leukemia-1 (MCL-1), which usually refers to the long isoform (MCL-1L) is frequently overexpressed in various types of cancer. However, MCL1 pre-mRNA can also undergo alternative splicing through exon skipping to yield the short isoform, MCL-1S.

View Article and Find Full Text PDF
Article Synopsis
  • The CMG helicase complex is essential for controlling gene expression during asymmetric cell divisions in C. elegans.
  • The specific component PSF-2 GINS2 is necessary for activating the pro-apoptotic gene egl-1, which is crucial for programmed cell death.
  • The study highlights CMG's role in influencing cell fates and suggests it affects gene expression beyond just egl-1 regulation.
View Article and Find Full Text PDF

Apoptosis is a fundamental process of all mammalian cells but exactly how it is regulated in different primary cells remains less explored. In most contexts, apoptosis is engaged to eliminate cells. However, postmitotic cells such as neurons must efficiently balance the need for developmental apoptosis versus the physiological needs for their long-term survival.

View Article and Find Full Text PDF

BCL-2 family proteins regulate apoptosis by initiating mitochondrial outer membrane permeabilization (MOMP). Activation of the MOMP effectors BAX and BAK is controlled by the interplay of anti-apoptotic BCL-2 proteins (e.g.

View Article and Find Full Text PDF

Proapoptotic activity of JNK-sensitive BH3-only proteins underpins ovarian cancer response to replication checkpoint inhibitors.

Mol Cancer

October 2024

Department of Molecular Pharmacology & Experimental Therapeutics, Mayo Clinic, 200 First Street, S.W., Rochester, MN, 55905, USA.

Article Synopsis
  • Researchers are studying drugs called replication checkpoint modulators (RCMs) that could help treat tough ovarian cancer, but they are not very effective by themselves.
  • When these drugs are used on cancer cells, they change certain proteins inside the cells, which makes them struggle to divide and can lead to cell death.
  • The study shows that these drugs can help shrink tumors even in stubborn cases, meaning they could be useful for patients with this type of cancer.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!